Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.53 |
| ▸ | DAO | P14920 | 1/20 | 0.53 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 4/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13423078 | 0.84 | F2 (0.57) | F2DAOGSK3BALDH1A1KDM4E | |
| SCHEMBL10534730 | 0.84 | F2 (0.57) | F2DAOGSK3BALDH1A1KDM4E | |
| SCHEMBL6623234 | 0.82 | F2 (0.55) | F2DAOGSK3BALDH1A1KDM4E | |
| SCHEMBL10861138 | 0.78 | DAO (0.55) | DAOALDH1A1KDM4EGAAHPGD | |
| SCHEMBL11457495 | 0.78 | F2 (0.59) | F2DAOGSK3BALDH1A1KDM4E | |
| SCHEMBL9593131 | 0.78 | F2 (0.59) | F2DAOGSK3BALDH1A1KDM4E | |
| SCHEMBL10352208 | 0.77 | F2 (0.48) | F2DAOGSK3BALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL10352335 | 0.75 | F2 (0.47) | F2DAOGSK3BALDH1A1KDM4E | |
| SCHEMBL2792677 | 0.73 | F2 (0.44) | F2DAOGSK3BALDH1A1KDM4E | |
| SCHEMBL11703462 | 0.73 | F2 (0.44) | F2DAOGSK3BALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3219207-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | The Trustees Of The University Of Pennsylvania (US) | 2017-09-20 | — | — | EP | disclosed |
| US-20170173016-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | NIH - DEITR | 2017-06-22 | — | — | US | disclosed |
| US-9649317-B2 | Heterocyclic compounds and their use for the treatment of neurodegenerative tauopathies | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2017-05-16 | — | — | US | disclosed |
| US-9649317-B2 | Heterocyclic compounds and their use for the treatment of neurodegenerative tauopathies | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2017-05-16 | — | — | US | disclosed |
| US-20150224105-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | NIH - DEITR | 2015-08-13 | — | — | US | disclosed |
| US-20150224105-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | NIH - DEITR | 2015-08-13 | — | — | US | disclosed |
| WO-2014047257-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-03-27 | — | — | WO | disclosed |
| EP-1978023-A1 | Pyridazines as fungicides | Bayer CropScience Aktiengesellschaft (DE) | 2008-10-08 | — | — | EP | disclosed |
| EP-1978023-A1 | Pyridazines as fungicides | Bayer CropScience Aktiengesellschaft (DE) | 2008-10-08 | — | — | EP | disclosed |
| EP-1972623-A1 | Arylpyridazines as fungicides | Bayer CropScience AG (DE) | 2008-09-24 | — | — | EP | disclosed |
| EP-1972623-A1 | Arylpyridazines as fungicides | Bayer CropScience AG (DE) | 2008-09-24 | — | — | EP | disclosed |
| EP-0248107-B1 | THIOPHENE RING-SUBSTITUTED ALPHA-(ALKYLAMINOPROPIONYL)-THIOPHENE DERIVATIVES, A PROCESS FOR PREPARING THEM AND PHARMACUETICAL COMPOSITIONS CONTAINING THEM | FERRER INTERNACIONAL, S.A. (ES) | 1990-07-18 | — | — | EP | disclosed |
| EP-0196001-B1 | THIOPHENE RING-SUBSTITUTED ALPHA-(ALKYLAMINOPROPIONYL)-THIOPHENE DERIVATIVES, A PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FERRER INTERNACIONAL, S.A. (ES) | 1989-01-25 | — | — | EP | disclosed |
| US-4719225-A | Thiophene ring-substituted α-(alkylaminopropionyl)-thiophenes and the method for preparing the same | FERRER INTERNACIONAL S.A. (ES) | 1988-01-12 | — | — | US | disclosed |
| EP-0248107-A1 | Thiophene ring-substituted alpha-(alkylaminopropionyl)-thiophene derivatives, a process for preparing them and pharmacuetical compositions containing them | FERRER INTERNACIONAL, S.A. (ES) | 1987-12-09 | — | — | EP | disclosed |
| EP-0196001-A1 | Thiophene ring-substituted alpha-(alkylaminopropionyl)-thiophene derivatives, a process for preparing them and pharmaceutical compositions containing them | FERRER INTERNACIONAL, S.A. (ES) | 1986-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170173016-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | MAPT, PRNP, PSEN2 | F2 4226/4885DAO 1838/4885GSK3B 154/4885 |
| US-20150224105-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEURODEGENERATIVE TAUOPATHIES | MAPT, SYNJ1, PARK7 | F2 1815/4885DAO 2911/4885GSK3B 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.